TruScreen December Newsletter

TruScreen Limited is pleased to provide a copy of its December 2018 Shareholder Newsletter. This gives an update on TruScreen's performance and highlights key initiatives underway. TruScreen has achieved significant growth in sales during the first half of the 2019 financial year. Highlights include: o Sales for the six months ending 30 September 2018 top NZD $1.4 million (unaudited) o 523% increase in sales on the corresponding period last year o Gross margin increasing as in-house manufacturing lowers unit costs The Shareholder Newsletter is available for viewing on the company website http://truscreen.com/investor-centre/newsletters/ -ENDS- For more information visit www.truscreen.com or contact: Martin Dillon TruScreen Chief Executive Officer Email: martindillon@truscreen.com Media Liaison Jackie Ellis Email: jackie@ellisandco.co.nz Phone: +64 27 246 2505 About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00327796 For:TRU Type:GENERAL Time:2018-12-04 08:31:01